Evidence map›Paper›PMID 34285513›Full record

ArticleJournal of asthma and allergy2021

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months.

Moritz Z Kayser, Nora Drick, Katrin Milger, Jan Fuge, Nikolaus Kneidinger, Stephanie Korn, Roland Buhl, Jürgen Behr, Tobias Welte, Hendrik Suhling

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of asthma and allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Observational
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Moritz Z KayserDepartment of Respiratory Medicine, Hannover Medical School, Hannover, Germany.ORCID 0000-0003-1421-1426
Nora DrickDepartment of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
Katrin MilgerDepartment of Medicine V, University Hospital, LMU, Munich, Germany.ORCID 0000-0003-2914-8773
Jan FugeDepartment of Respiratory Medicine, Hannover Medical School, Hannover, Germany.ORCID 0000-0003-2926-3608
Nikolaus KneidingerDepartment of Medicine V, University Hospital, LMU, Munich, Germany.ORCID 0000-0001-7583-0453
Stephanie KornClinical Research Centre for Respiratory Medicine, Mainz, Germany.
Roland BuhlPulmonary Department, Mainz University Hospital, Mainz, Germany.
Jürgen BehrDepartment of Medicine V, University Hospital, LMU, Munich, Germany.
Tobias WelteDepartment of Respiratory Medicine, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-9947-7356
Hendrik SuhlingDepartment of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
Medizinische Hochschule Hannover · DELMU Klinikum · DEJohannes Gutenberg University Mainz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTreatment of severe eosinophilic asthma (SEA) has been revolutionized by the development of monoclonal antibodies targeting underlying immunological pathways of eosinophilic asthma. Two of the most frequently used antibodies in clinical practice are mepolizumab, targeting interleukin (IL) 5 and benralizumab, targeting the IL5 receptor alpha. The comparative treatment efficacy of these antibodies remains unclear, particularly regarding long-term outcomes. PATIENTS AND

methodsIn this multicenter, retrospective study, we included 123 patients treated with mepolizumab and 64 patients treated with benralizumab for 12 months at one of three study sites in Germany. Data were collected at baseline and after 6 and 12 months of therapy. Endpoints were changes in pulmonary function (PF), exacerbation rate, oral corticosteroid (OCS) use and dose, asthma control test (ACT) score and fractional exhaled nitric oxide (FeNO) levels.

resultsBoth mepolizumab and benralizumab led to significant improvements in PF with an increase in median forced expiratory volume (FEV1) after 12 months from 59% to 74% for mepolizumab and 63% to 72% for benralizumab. Treatment also led to significant improvements in ACT scores after 12 months (mepolizumab: 13 [interquartile range (IQR) 9-17] to 19 [IQR 15-23]; benralizumab: 12 [IQR 9-16] to 22 [IQR 16-25]) as well as a reduction of mean OCS dose (mepolizumab 8 mg [IQR 5-12.5 mg] median prednisolone equivalent at baseline to 5 mg [IQR 3-7.5 mg]; benralizumab 7.5 mg [IQR 5-15 mg] to 5 mg [IQR 2-10 mg]). The exacerbation rates were reduced significantly, irrespective of the treatment. Overall, changes were similar after 6 and 12 months of therapy.

conclusionBoth mepolizumab and benralizumab are highly effective in the long-term treatment of SEA, with no clinically relevant differences in outcomes after 12 months of therapy. In both groups, improvements were similar after 6 and 12 months of therapy, underlining the feasibility of early treatment evaluation.

Indexed as

asthma controlinterleukin-5interleukin-5-receptorlungsevere eosinophilic asthmatreatment response

Identifiers

PMID34285513
PMCPMC8285237
OpenAlexW3181891508

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.